Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.
Identifieur interne : 000364 ( PubMed/Curation ); précédent : 000363; suivant : 000365Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.
Auteurs : Philippe Mayaud [Royaume-Uni] ; Jérôme Legoff ; Helen A. Weiss ; Gérard Grésenguet ; Khonde Nzambi ; Hicham Bouhlal ; Eric Frost ; Jacques Pépin ; Jean-Elie Malkin ; Richard J. Hayes ; David C W. Mabey ; Laurent BélecSource :
- The Journal of infectious diseases [ 0022-1899 ] ; 2009.
Descripteurs français
- KwdFr :
- ADN viral (métabolisme), ARN viral (métabolisme), ARN viral (sang), Aciclovir (usage thérapeutique), Adolescent, Adulte, Antiviraux (usage thérapeutique), Femelle, Ghana (épidémiologie), Herpès génital (), Herpès génital (traitement médicamenteux), Herpès génital (épidémiologie), Herpèsvirus humain de type 2 (génétique), Herpèsvirus humain de type 2 (métabolisme), Humains, Infections à VIH (), Infections à VIH (virologie), Méthode en double aveugle, République centrafricaine (épidémiologie), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (métabolisme).
- MESH :
- génétique : Herpèsvirus humain de type 2, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- métabolisme : ADN viral, ARN viral, Herpèsvirus humain de type 2, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- sang : ARN viral.
- traitement médicamenteux : Herpès génital.
- usage thérapeutique : Aciclovir, Antiviraux.
- virologie : Infections à VIH.
- épidémiologie : Ghana, Herpès génital, République centrafricaine.
- Adolescent, Adulte, Femelle, Herpès génital, Humains, Infections à VIH, Méthode en double aveugle.
- Wicri :
- geographic : République centrafricaine, Ghana.
English descriptors
- KwdEn :
- Acyclovir (therapeutic use), Adolescent, Adult, Antiviral Agents (therapeutic use), Central African Republic (epidemiology), DNA, Viral (metabolism), Double-Blind Method, Female, Ghana (epidemiology), HIV Infections (complications), HIV Infections (virology), HIV-1 (genetics), HIV-1 (metabolism), Herpes Genitalis (complications), Herpes Genitalis (drug therapy), Herpes Genitalis (epidemiology), Herpesvirus 2, Human (genetics), Herpesvirus 2, Human (metabolism), Humans, RNA, Viral (blood), RNA, Viral (metabolism).
- MESH :
- chemical , blood : RNA, Viral.
- chemical , metabolism : DNA, Viral, RNA, Viral.
- chemical , therapeutic use : Acyclovir, Antiviral Agents.
- geographic , epidemiology : Central African Republic, Ghana.
- complications : HIV Infections, Herpes Genitalis.
- drug therapy : Herpes Genitalis.
- epidemiology : Herpes Genitalis.
- genetics : HIV-1, Herpesvirus 2, Human.
- metabolism : HIV-1, Herpesvirus 2, Human.
- virology : HIV Infections.
- Adolescent, Adult, Double-Blind Method, Female, Humans.
Abstract
Little is known about the impact of episodic treatment of herpes on human immunodeficiency virus type 1 (HIV-1).
DOI: 10.1086/599991
PubMed: 19530940
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000364
Links to Exploration step
pubmed:19530940Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.</title><author><name sortKey="Mayaud, Philippe" sort="Mayaud, Philippe" uniqKey="Mayaud P" first="Philippe" last="Mayaud">Philippe Mayaud</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. philippe.mayaud@lshtm.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London</wicri:regionArea></affiliation></author><author><name sortKey="Legoff, Jerome" sort="Legoff, Jerome" uniqKey="Legoff J" first="Jérôme" last="Legoff">Jérôme Legoff</name></author><author><name sortKey="Weiss, Helen A" sort="Weiss, Helen A" uniqKey="Weiss H" first="Helen A" last="Weiss">Helen A. Weiss</name></author><author><name sortKey="Gresenguet, Gerard" sort="Gresenguet, Gerard" uniqKey="Gresenguet G" first="Gérard" last="Grésenguet">Gérard Grésenguet</name></author><author><name sortKey="Nzambi, Khonde" sort="Nzambi, Khonde" uniqKey="Nzambi K" first="Khonde" last="Nzambi">Khonde Nzambi</name></author><author><name sortKey="Bouhlal, Hicham" sort="Bouhlal, Hicham" uniqKey="Bouhlal H" first="Hicham" last="Bouhlal">Hicham Bouhlal</name></author><author><name sortKey="Frost, Eric" sort="Frost, Eric" uniqKey="Frost E" first="Eric" last="Frost">Eric Frost</name></author><author><name sortKey="Pepin, Jacques" sort="Pepin, Jacques" uniqKey="Pepin J" first="Jacques" last="Pépin">Jacques Pépin</name></author><author><name sortKey="Malkin, Jean Elie" sort="Malkin, Jean Elie" uniqKey="Malkin J" first="Jean-Elie" last="Malkin">Jean-Elie Malkin</name></author><author><name sortKey="Hayes, Richard J" sort="Hayes, Richard J" uniqKey="Hayes R" first="Richard J" last="Hayes">Richard J. Hayes</name></author><author><name sortKey="Mabey, David C W" sort="Mabey, David C W" uniqKey="Mabey D" first="David C W" last="Mabey">David C W. Mabey</name></author><author><name sortKey="Belec, Laurent" sort="Belec, Laurent" uniqKey="Belec L" first="Laurent" last="Bélec">Laurent Bélec</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19530940</idno><idno type="pmid">19530940</idno><idno type="doi">10.1086/599991</idno><idno type="wicri:Area/PubMed/Corpus">000364</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000364</idno><idno type="wicri:Area/PubMed/Curation">000364</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000364</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.</title><author><name sortKey="Mayaud, Philippe" sort="Mayaud, Philippe" uniqKey="Mayaud P" first="Philippe" last="Mayaud">Philippe Mayaud</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. philippe.mayaud@lshtm.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London</wicri:regionArea></affiliation></author><author><name sortKey="Legoff, Jerome" sort="Legoff, Jerome" uniqKey="Legoff J" first="Jérôme" last="Legoff">Jérôme Legoff</name></author><author><name sortKey="Weiss, Helen A" sort="Weiss, Helen A" uniqKey="Weiss H" first="Helen A" last="Weiss">Helen A. Weiss</name></author><author><name sortKey="Gresenguet, Gerard" sort="Gresenguet, Gerard" uniqKey="Gresenguet G" first="Gérard" last="Grésenguet">Gérard Grésenguet</name></author><author><name sortKey="Nzambi, Khonde" sort="Nzambi, Khonde" uniqKey="Nzambi K" first="Khonde" last="Nzambi">Khonde Nzambi</name></author><author><name sortKey="Bouhlal, Hicham" sort="Bouhlal, Hicham" uniqKey="Bouhlal H" first="Hicham" last="Bouhlal">Hicham Bouhlal</name></author><author><name sortKey="Frost, Eric" sort="Frost, Eric" uniqKey="Frost E" first="Eric" last="Frost">Eric Frost</name></author><author><name sortKey="Pepin, Jacques" sort="Pepin, Jacques" uniqKey="Pepin J" first="Jacques" last="Pépin">Jacques Pépin</name></author><author><name sortKey="Malkin, Jean Elie" sort="Malkin, Jean Elie" uniqKey="Malkin J" first="Jean-Elie" last="Malkin">Jean-Elie Malkin</name></author><author><name sortKey="Hayes, Richard J" sort="Hayes, Richard J" uniqKey="Hayes R" first="Richard J" last="Hayes">Richard J. Hayes</name></author><author><name sortKey="Mabey, David C W" sort="Mabey, David C W" uniqKey="Mabey D" first="David C W" last="Mabey">David C W. Mabey</name></author><author><name sortKey="Belec, Laurent" sort="Belec, Laurent" uniqKey="Belec L" first="Laurent" last="Bélec">Laurent Bélec</name></author></analytic><series><title level="j">The Journal of infectious diseases</title><idno type="ISSN">0022-1899</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acyclovir (therapeutic use)</term><term>Adolescent</term><term>Adult</term><term>Antiviral Agents (therapeutic use)</term><term>Central African Republic (epidemiology)</term><term>DNA, Viral (metabolism)</term><term>Double-Blind Method</term><term>Female</term><term>Ghana (epidemiology)</term><term>HIV Infections (complications)</term><term>HIV Infections (virology)</term><term>HIV-1 (genetics)</term><term>HIV-1 (metabolism)</term><term>Herpes Genitalis (complications)</term><term>Herpes Genitalis (drug therapy)</term><term>Herpes Genitalis (epidemiology)</term><term>Herpesvirus 2, Human (genetics)</term><term>Herpesvirus 2, Human (metabolism)</term><term>Humans</term><term>RNA, Viral (blood)</term><term>RNA, Viral (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN viral (métabolisme)</term><term>ARN viral (métabolisme)</term><term>ARN viral (sang)</term><term>Aciclovir (usage thérapeutique)</term><term>Adolescent</term><term>Adulte</term><term>Antiviraux (usage thérapeutique)</term><term>Femelle</term><term>Ghana (épidémiologie)</term><term>Herpès génital ()</term><term>Herpès génital (traitement médicamenteux)</term><term>Herpès génital (épidémiologie)</term><term>Herpèsvirus humain de type 2 (génétique)</term><term>Herpèsvirus humain de type 2 (métabolisme)</term><term>Humains</term><term>Infections à VIH ()</term><term>Infections à VIH (virologie)</term><term>Méthode en double aveugle</term><term>République centrafricaine (épidémiologie)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>DNA, Viral</term><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acyclovir</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Central African Republic</term><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term><term>Herpes Genitalis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Herpes Genitalis</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Herpes Genitalis</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV-1</term><term>Herpesvirus 2, Human</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Herpèsvirus humain de type 2</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>HIV-1</term><term>Herpesvirus 2, Human</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>ADN viral</term><term>ARN viral</term><term>Herpèsvirus humain de type 2</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>ARN viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Herpès génital</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Aciclovir</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Ghana</term><term>Herpès génital</term><term>République centrafricaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Femelle</term><term>Herpès génital</term><term>Humains</term><term>Infections à VIH</term><term>Méthode en double aveugle</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>République centrafricaine</term><term>Ghana</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Little is known about the impact of episodic treatment of herpes on human immunodeficiency virus type 1 (HIV-1).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19530940</PMID><DateCreated><Year>2009</Year><Month>07</Month><Day>09</Day></DateCreated><DateCompleted><Year>2009</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1899</ISSN><JournalIssue CitedMedium="Print"><Volume>200</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.</ArticleTitle><Pagination><MedlinePgn>216-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1086/599991</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Little is known about the impact of episodic treatment of herpes on human immunodeficiency virus type 1 (HIV-1).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Women from Ghana and the Central African Republic who had genital ulcers were enrolled in a randomized, double-blind, placebo-controlled trial of acyclovir plus antibacterials and were monitored for 28 days. Ulcer etiologies and detection of lesional HIV-1 RNA were determined by polymerase chain reaction (PCR). Cervicovaginal HIV-1 RNA and herpes simplex virus type 2 (HSV-2) DNA and plasma HIV-1 RNA were quantitated by real-time PCR. Primary analyses included 118 HIV-1-infected women with HSV-2 ulcers (54 of whom were given acyclovir and 64 of whom were given placebo).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Acyclovir had little impact on (1) detection of cervicovaginal HIV-1 RNA (risk ratio [RR], 0.96; 95% confidence interval [CI], 0.8-1.2) at day 7 of treatment, (2) the mean cervicovaginal HIV-1 RNA load (-0.06 log(10) copies/mL; 95% CI, -0.4 to 0.3 log(10) copies/mL) at day 7 of treatment, or (3) the plasma HIV-1 RNA load (+0.09 log(10) copies/mL; 95% CI, -0.1 to 0.3 log(10) copies/mL) at day 14 of treatment. At day 7, women receiving acyclovir were less likely to have detectable lesional HIV-1 RNA (RR, 0.70; 95% CI, 0.4-1.2) or cervicovaginal HSV-2 DNA (RR, 0.69; 95% CI, 0.4-1.3), had a lower quantity of HSV-2 DNA (-0.99 log(10) copies/mL; 95% CI, -1.8 to -0.2 log(10) copies/mL), and were more likely to have a healed ulcer (RR, 1.26; 95% CI, 0.9-1.9).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Episodic therapy for herpes reduced the quantity of cervicovaginal HSV-2 DNA and slightly improved ulcer healing, but it did not decrease genital and plasma HIV-1 RNA loads.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov identifier NCT00158483 .</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mayaud</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. philippe.mayaud@lshtm.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legoff</LastName><ForeName>Jérôme</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Helen A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Grésenguet</LastName><ForeName>Gérard</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Nzambi</LastName><ForeName>Khonde</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bouhlal</LastName><ForeName>Hicham</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pépin</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Malkin</LastName><ForeName>Jean-Elie</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Mabey</LastName><ForeName>David C W</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Bélec</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><CollectiveName>ANRS 1212 Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00158483</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>MRC_G0700837</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4HES1O11F</RegistryNumber><NameOfSubstance UI="D000212">Acyclovir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000212" MajorTopicYN="N">Acyclovir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002488" MajorTopicYN="N" Type="Geographic">Central African Republic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006558" MajorTopicYN="N">Herpes Genitalis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018258" MajorTopicYN="N">Herpesvirus 2, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Chemin</LastName><ForeName>Cécile</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lecerf</LastName><ForeName>Maxime</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>LeG</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Si-Mohamed</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longo</LastName><ForeName>Jean-de-Dieu</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agyarko-Poku</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asamoah-Adu</LastName><ForeName>Comfort</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dzokoto</LastName><ForeName>Agnes</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deslandes</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19530940</ArticleId><ArticleId IdType="doi">10.1086/599991</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000364 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000364 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:19530940
|texte= Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:19530940" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |